JP6473738B2 - チオトロピウム乾燥粉末 - Google Patents

チオトロピウム乾燥粉末 Download PDF

Info

Publication number
JP6473738B2
JP6473738B2 JP2016505482A JP2016505482A JP6473738B2 JP 6473738 B2 JP6473738 B2 JP 6473738B2 JP 2016505482 A JP2016505482 A JP 2016505482A JP 2016505482 A JP2016505482 A JP 2016505482A JP 6473738 B2 JP6473738 B2 JP 6473738B2
Authority
JP
Japan
Prior art keywords
dry powder
less
microns
dry
inhalable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016505482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515576A (ja
JP2016515576A5 (https=
Inventor
シー． スン，ジーン
シー． スン，ジーン
マンザネド，ダイアナ
エム． ペリー，ジェイスン
エム． ペリー，ジェイスン
エイチ． デハーン，ウェスリー
エイチ． デハーン，ウェスリー
トラウトマン，ブライアン
Original Assignee
パルマトリックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パルマトリックス，インコーポレイテッド filed Critical パルマトリックス，インコーポレイテッド
Publication of JP2016515576A publication Critical patent/JP2016515576A/ja
Publication of JP2016515576A5 publication Critical patent/JP2016515576A5/ja
Application granted granted Critical
Publication of JP6473738B2 publication Critical patent/JP6473738B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016505482A 2013-04-01 2014-03-13 チオトロピウム乾燥粉末 Active JP6473738B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361807063P 2013-04-01 2013-04-01
US61/807,063 2013-04-01
US201361874146P 2013-09-05 2013-09-05
US61/874,146 2013-09-05
US201461925400P 2014-01-09 2014-01-09
US61/925,400 2014-01-09
PCT/US2014/025660 WO2014165303A1 (en) 2013-04-01 2014-03-13 Tiotropium dry powders

Publications (3)

Publication Number Publication Date
JP2016515576A JP2016515576A (ja) 2016-05-30
JP2016515576A5 JP2016515576A5 (https=) 2017-04-20
JP6473738B2 true JP6473738B2 (ja) 2019-02-20

Family

ID=50693973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016505482A Active JP6473738B2 (ja) 2013-04-01 2014-03-13 チオトロピウム乾燥粉末

Country Status (11)

Country Link
US (2) US9737518B2 (https=)
EP (1) EP2981247B1 (https=)
JP (1) JP6473738B2 (https=)
KR (1) KR20150135328A (https=)
CN (1) CN105324106A (https=)
AU (1) AU2014248455B2 (https=)
CA (1) CA2907566C (https=)
HK (1) HK1221175A1 (https=)
MX (1) MX2015013845A (https=)
RU (1) RU2015146871A (https=)
WO (1) WO2014165303A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) 2014-01-24 2018-02-24
WO2016057641A1 (en) * 2014-10-08 2016-04-14 Pulmatrix Operating Company, Inc. Formulations containing tiotropium, amino acid and acid and methods thereof
GEAP202014761A (en) * 2015-10-23 2020-04-27 Arven Ilac Sanayi Ve Ticaret As Blister for inhalable formulation of tiotropium bromide
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
EP3525759A1 (en) * 2016-10-14 2019-08-21 Pulmatrix Operating Company, Inc. Antifungal dry powders
WO2019071147A1 (en) * 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
PL3505157T3 (pl) * 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
AU2019225031B2 (en) * 2018-02-26 2024-04-18 Shin Nippon Biomedical Laboratories, Ltd. Powder preparation, cartridge, and device
KR20250002710A (ko) 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
EP3846825A4 (en) 2018-09-05 2022-11-02 Sensory Cloud, LLC FORMULATIONS AND COMPOSITIONS FOR ORTHO- AND/OR RETRO-NASAL DELIVERY AND RELATED SYSTEMS, METHODS AND ARTICLES
CN110161142A (zh) * 2019-06-11 2019-08-23 珠海瑞思普利生物制药有限公司 一种表征干粉吸入制剂在呼吸系统空气动力学的仿真装置
BE1027612B1 (fr) * 2019-09-10 2021-05-03 Aquilon Pharmaceuticals Microparticules en forme de balle de golf pour une utilisation dans le traitement et la prevention de maladies pulmonaires
WO2022187222A1 (en) * 2021-03-03 2022-09-09 Pulmatrix Operating Company, Inc. Dihydroergotamine dry power formulations and methods of use
EP4108230A1 (en) * 2021-06-24 2022-12-28 Laboratoires SMB New dry powder composition of tiotropium for inhalation
CN114272228B (zh) * 2022-01-04 2023-08-22 丽珠医药集团股份有限公司 噻托溴铵吸入微球及其制备方法和吸入式制剂
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
CN117233286A (zh) * 2023-09-19 2023-12-15 南京力成药业有限公司 一种噻托溴铵的定量检测方法

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1575050A1 (de) 1966-01-12 1972-04-13 Misto Gen Equipment Co Ultraschall-Nebelerzeugungsgeraet
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4085893A (en) 1974-03-20 1978-04-25 Durley Iii Benton A Ultrasonic humidifiers, atomizers and the like
US4193009A (en) 1976-01-26 1980-03-11 Durley Benton A Iii Ultrasonic piezoelectric transducer using a rubber mounting
JPS5550437U (https=) 1978-09-28 1980-04-02
US4233405A (en) 1979-10-10 1980-11-11 Rohm And Haas Company Process for spray drying enzymes
DE3229179C2 (de) 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
US4643351A (en) 1984-06-14 1987-02-17 Tokyo Sanyo Electric Co. Ultrasonic humidifier
US4637815A (en) 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
FI82808C (fi) 1987-12-31 1991-04-25 Etelae Haemeen Keuhkovammayhdi Ultraljudfinfoerdelningsanordning.
US4899914A (en) 1988-11-04 1990-02-13 Ciba-Geigy Corporation Method for producing a sterile preservative-free aerosol saline solution
US4921639A (en) 1988-11-09 1990-05-01 Bernard Chiu Ultrasonic humidifier
US4881541A (en) 1988-12-21 1989-11-21 The Regents Of The University Of California Vaporizer for an anesthetic having a vapor pressure about one atmosphere
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
US5571535A (en) 1990-11-30 1996-11-05 Flowers; Marianne Treatment of topical infections
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
JPH05123398A (ja) 1991-11-06 1993-05-21 Tsunemasa Kamiyama 咽喉保護吸入剤並びに吸入器具
GB2265845B (en) 1991-11-12 1996-05-01 Medix Ltd A nebuliser and nebuliser control system
US5466680A (en) 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
JP3961029B2 (ja) 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5898037A (en) 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
NZ328476A (en) 1993-06-24 1999-05-28 Astra Ab Use of a two component insulin preparation in an inhalation device
US5514665A (en) 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
JP3414539B2 (ja) 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JP3061862B2 (ja) 1994-10-14 2000-07-10 山之内製薬株式会社 アゾール誘導体
US5863563A (en) 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US20050054682A1 (en) 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US5881720A (en) 1997-04-29 1999-03-16 The Procter & Gamble Company Method of delivering halotherapy
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
AU749751B2 (en) 1998-04-08 2002-07-04 Eli Lilly And Company Pulmonary and nasal delivery of raloxifene
US5883084A (en) 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
FR2780285B1 (fr) 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
JP3312216B2 (ja) 1998-12-18 2002-08-05 オムロン株式会社 噴霧装置
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
AU4979700A (en) 1999-05-03 2000-11-17 Battelle Memorial Institute Compositions for aerosolization and inhalation
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
AU768299B2 (en) 1999-08-25 2003-12-04 Alkermes, Inc. Formulation for spray-drying large porous particles
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
DE60025019T2 (de) 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
AU772096B2 (en) 2000-03-14 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6637432B2 (en) 2000-05-09 2003-10-28 Iep Pharmaceutical Devices Inc. Inhalation actuated device
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1296651E (pt) 2000-06-27 2008-02-12 Vectura Ltd Método para fazer partículas para serem usadas numa composição farmacêutica
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6669959B1 (en) 2000-07-18 2003-12-30 Aeropharm Technology Incorporated Modulated release particles for lung delivery
AU2001278131A1 (en) 2000-08-01 2002-02-13 Shofner Engineering Associates, Inc. Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6572849B2 (en) 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US20040081627A1 (en) 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
EP2283818B1 (en) 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
CA2432319A1 (en) 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
DE10064816A1 (de) 2000-12-22 2002-06-27 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Anticholinergikums
PT2301524E (pt) 2000-12-27 2013-07-10 Gilead Sciences Inc Aztreonam inalável sem arginina para tratamento e prevenção de infecções bacterianas pulmonares
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
EP1359902B1 (en) 2001-02-06 2007-08-08 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
US6550472B2 (en) 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
US20030022829A1 (en) 2001-03-30 2003-01-30 Wendy Maury Novel antiviral activities primate theta defensins and mammalian cathelicidins
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6511050B2 (en) 2001-05-02 2003-01-28 Dynamo Aviation, Inc. Humidifier
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
JP2003074919A (ja) 2001-08-31 2003-03-12 Sunbow Precision Co Ltd 複合式加湿器
WO2003035028A1 (en) 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20030203930A1 (en) 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
CA2465675C (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
IL161446A0 (en) 2001-11-26 2004-09-27 Daiichi Suntory Pharma Co Ltd Medicinal compositions for nasal absorption
US6851626B2 (en) 2002-01-07 2005-02-08 Aerogen, Inc. Methods and devices for nebulizing fluids
GB2384198B (en) 2002-01-18 2005-03-02 Profile Drug Delivery Ltd Nebulizer metering
GB0217199D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
JP4384503B2 (ja) 2002-03-20 2009-12-16 アルカーメス，インコーポレイテッド レボドパの肺送達
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB0209782D0 (en) 2002-04-29 2002-06-05 Glaxo Group Ltd Medicament dispenser
US20050220720A1 (en) 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
EP1503744A1 (en) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
JP4533134B2 (ja) 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
WO2004002551A2 (en) 2002-06-28 2004-01-08 Advanced Inhalation Research, Inc. Inhalable epinephrine
GB0217198D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7112572B2 (en) 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
WO2004030659A1 (en) 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
WO2004047735A2 (en) 2002-11-22 2004-06-10 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
CN1194062C (zh) 2003-04-04 2005-03-23 王泽斌 一种融雪融冰组合物及其制备方法和应用
EA010948B1 (ru) 2003-05-01 2008-12-30 Инноджен Калбиотех Пте Лтд. Фармацевтическая композиция, содержащая лактат, и ее применение
ATE501766T1 (de) 2003-05-20 2011-04-15 James F Collins Ophthalmisches arzneimittelabgabesystem
US7195179B2 (en) 2003-06-01 2007-03-27 Piezo Technologies Piezoelectric mist generation device
JP2009514779A (ja) 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
GB0324918D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0324897D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
US7968717B2 (en) 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
SE0303270L (sv) 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
KR20050056622A (ko) 2003-12-10 2005-06-16 주식회사 대우일렉트로닉스 플레쉬롬 다운로드 장치
EP1701714A2 (en) 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
EP1734962A4 (en) 2004-03-30 2010-07-14 Painceptor Pharma Corp COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
CA2602596A1 (en) 2004-03-30 2005-10-13 Malcolm King Compositions and methods for improved mucus function
US20050281740A1 (en) 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
GB0415789D0 (en) * 2004-07-15 2004-08-18 Astrazeneca Ab Novel combination
MX2007000979A (es) 2004-07-26 2007-07-11 Cotherix Inc Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada.
DE102004041253A1 (de) 2004-08-26 2006-03-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Verfahren zur Herstellung von Tiotropiumsalzen
US20070259856A1 (en) 2004-09-07 2007-11-08 Sanjay Kumar Method for Activating Trpv4 Channel Receptors by Agonists
US20060073173A1 (en) 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
WO2006084131A2 (en) 2005-02-01 2006-08-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection
CN102312963B (zh) 2005-02-10 2015-03-11 博格华纳公司 双离合器变速器机构的功率通量配置
WO2006102438A2 (en) 2005-03-23 2006-09-28 Ihc Intellectual Asset Management, Llc Methods and compositions for irrigation of mucosal tissues
US20060229366A1 (en) 2005-04-07 2006-10-12 Lifschitz Carlos H Method for preventing or treating respiratory infections in infants
BRPI0609295A2 (pt) 2005-05-02 2010-03-23 Boehringer Ingelheim Int formas cristalinas de brometo de tiotràpio, composiÇço farmacÊutica, uso e mÉtodo para preparar as mesmas
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EP2402001A1 (en) 2005-05-18 2012-01-04 Pulmatrix, Inc. Formulations for alteration of biophysical properties of mucosal lining
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
AU2006308914A1 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Compositions and methods for identifying modulators of TRPV2
GB0523576D0 (en) 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
RS52663B2 (sr) 2005-12-19 2018-05-31 Sicor Inc Nova kristalna forma tiotropijum bromida i proces njene pripreme
JP2009524646A (ja) 2006-01-27 2009-07-02 ザ・プロヴォスト，フェローズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホーリー・アンド・アンディヴァイデッド・トリニティー・オブ・クイーン・エリザベス，ニア・ダブリン 多孔性微粒子の製造方法
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
US20080051582A1 (en) 2006-07-10 2008-02-28 Sicor Inc. Process for the preparation of tiotropium bromide
MX2009001533A (es) 2006-08-11 2009-02-18 Panacea Biotec Ltd Particulas para el suministro de ingredientes activos, procedimiento de elaboracion y sus composiciones.
WO2008025560A1 (en) 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
US20080063722A1 (en) 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
WO2008065666A2 (en) 2006-11-29 2008-06-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Uses of incensole, incensole acetate and derivatives thereof
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
GB0625322D0 (en) 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
GB0719518D0 (en) 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
EP2050437A1 (en) 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
EP2080508A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
WO2009140587A1 (en) 2008-05-15 2009-11-19 Novartis Ag Pulmonary delivery of a fluoroquinolone
EP2172190A1 (en) 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
GB0818476D0 (en) 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
CA2744655A1 (en) 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
CA2754670A1 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Anti-influenza formulations and methods
JP2012522011A (ja) 2009-03-26 2012-09-20 パルマトリックス，インコーポレイテッド 気道感染症を治療するための医薬製剤および方法
CA2754691C (en) 2009-03-26 2019-07-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20120058198A1 (en) 2009-03-26 2012-03-08 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
CA2754684A1 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
EP2411008B1 (en) 2009-03-27 2017-03-22 Mahmut Bilgic Complexes of tiotropium with improved properties of solubility and stability
US20120101077A1 (en) 2009-04-24 2012-04-26 Schering Corporation Agglomerate formulations useful in dry powder inhalers
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
TR200907236A2 (tr) 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropyum kuru toz formülasyonunun blister ambalajda taşınması.
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
RU2017144619A (ru) * 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
EP2627317A4 (en) 2010-10-15 2014-08-20 Glaxo Group Ltd MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
PT106094A (pt) 2012-01-13 2013-07-15 Hovione Farmaciencia S A Administração por inalação de formulações com dose elevada

Also Published As

Publication number Publication date
EP2981247B1 (en) 2023-06-07
CA2907566A1 (en) 2014-10-09
EP2981247A1 (en) 2016-02-10
US9737518B2 (en) 2017-08-22
RU2015146871A (ru) 2017-05-10
CN105324106A (zh) 2016-02-10
JP2016515576A (ja) 2016-05-30
KR20150135328A (ko) 2015-12-02
WO2014165303A1 (en) 2014-10-09
MX2015013845A (es) 2016-05-09
HK1221175A1 (zh) 2017-05-26
US20160120855A1 (en) 2016-05-05
RU2015146871A3 (https=) 2018-03-05
AU2014248455B2 (en) 2018-12-06
CA2907566C (en) 2023-08-22
BR112015025160A2 (pt) 2017-07-18
AU2014248455A1 (en) 2015-10-15
US20170312258A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
JP6473738B2 (ja) チオトロピウム乾燥粉末
JP7623854B2 (ja) 乾燥粉末配合および使用方法
CN103052379A (zh) 包含磷酸二酯酶抑制剂的干粉制剂
JP7549534B2 (ja) イトラコナゾールを含む肺内投与のための抗真菌配合物
KR20180003572A (ko) 다중 약물 취성 매트릭스 조성물
US10532041B2 (en) Formulation comprising glycopyrrolate, method and apparatus
CN116687887A (zh) 用于吸入的干粉制剂
RU2742376C1 (ru) Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик
CA2963666A1 (en) Formulations containing tiotropium, amino acid and acid and methods thereof
KR102898819B1 (ko) 흡입용 건조 분말 제제를 위한 신규 담체 입자
US20170304198A1 (en) Improved stability of dry powders containing tiotropium and amino acid
US20240033218A1 (en) Dihydroergotamine dry powder formulations and methods of use
RU2823554C1 (ru) Новые частицы носителя для сухих порошковых составов для ингаляции
BR112015025160B1 (pt) Pós secos de tiotrópio
HK40064779A (en) Novel carrier particles for dry powder formulations for inhalation
US20120097160A1 (en) Agglomerate formulations including active pharmaceutical agents with targeted particle sizes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190128

R150 Certificate of patent or registration of utility model

Ref document number: 6473738

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250